Clinical trials: Neoplasm of Head of Pancreas
Cancer
Early Intervention vs. Standard Palliative Care in Improving End-of-Life Care in Advanced Cancer Patients
RATIONALE: Palliative care may help patients with advanced cancer live more comfortably. PURPOSE: This randomized clinical trial is studying an early intervention palliative care program to see how well it works compared to a…
- Trial name
- NCT00253383
- Testing
- counseling intervention, educational intervention, psychosocial assessment and care
- Where
- 2 sites in United States
- Volunteers
- 329 people
- Sponsor
- Dartmouth-Hitchcock Medical Center
Depression, Fatigue
Programs To Support You During Chemotherapy
This randomized pilot trial studies how well two supportive programs work for improving fatigue and depressive symptoms in patients with GI undergoing chemotherapy.
- Conditions
- Depression, Fatigue, Stage IIA Colorectal Cancer, Stage IIB Colorectal Cancer
- Trial name
- PRO-YOU (NCT02489422)
- Testing
- Laboratory Biomarker Analysis, Questionnaire Administration, Daily Survey Administration
- Where
- 2 sites in United States
- Volunteers
- 44 people
- Sponsor
- Wake Forest University Health Sciences
Squamous Cell Carcinoma of Head and Neck, Non-small Cell Lung Cancer
A Phase 1/2, Open-label, Multi-center Study of the Safety and Efficacy of Alomfilimab (KY1044) as Single Agent and in Combination With Anti-PD-L1 (Atezolizumab) in Adult Patients With Selected Advanced Malignancies
A Phase 1/2, open label, multi-center study to evaluate the safety, efficacy and tolerability of alomfilimab as single agent and in combination with anti-PD-L1 (atezolizumab) in adult patients with selected advanced malignancies…
- Conditions
- Squamous Cell Carcinoma of Head and Neck, Non-small Cell Lung Cancer, Hepatocellular Carcinoma, Esophageal Cancer
- Trial name
- NCT03829501
- Testing
- Alomfilimab, Atezolizumab
- Where
- 22 sites in United States, Hungary and 4 more
- Volunteers
- 222 people
- Sponsor
- Kymab Limited
Cystic Fibrosis
Prospective Observational Study to Evaluate Biomarkers of Aminoglycoside Nephrotoxicity in Patients With Cystic Fibrosis
The project is designed to test new biomarkers that are more sensitive than the current standard in detecting injury to the proximal kidney tubule and will establish better criteria for when kidney safety concerns may halt…
- Trial name
- NCT01543620
- Where
- 3 sites in United States
- Volunteers
- 150 people
- Sponsor
- Foundation for the National Institutes of Health
Pancreatic Cancer, Pancreatic Adenocarcinoma
EUS BD vs ERCP TP for Pancreatic Cancer
This Endoscopic Ultrasound guided Biliary Drainage (EUS-BD) vs. Endoscopic Retrograde Cholangiopancreatography (ERCP-TP) trial (BILPAL) is a randomized controlled multicenter trial that will provide evidence whether or not…
- Conditions
- Pancreatic Cancer, Pancreatic Adenocarcinoma, Biliary Tract Neoplasms, Biliary Duct Obstruction
- Trial name
- BILPAL (NCT03063554)
- Testing
- Endoscopic Ultrasound Guided Biliary Drainage, ERCP
- Where
- United States
- Volunteers
- 120 people
- Sponsor
- Weill Medical College of Cornell University
Solid Tumor, Adult, Epithelial Ovarian Cancer
Study of CBX-12 in Subjects With Advanced or Metastatic Refractory Solid Tumors
This is a first-in-human, Phase 1/2 open-label, multicenter, dose-escalation, safety, pharmacokinetics (PK), and biomarker study of CBX-12 in subjects with advanced or metastatic refractory solid tumors.
- Conditions
- Solid Tumor, Adult, Epithelial Ovarian Cancer, Small Cell Lung Carcinoma, Breast Cancer
- Trial name
- NCT04902872
- Testing
- CBX-12
- Where
- 4 sites in United States
- Volunteers
- 69 people
- Sponsor
- Cybrexa Therapeutics
Pancreatic Cancer
Nordic Pancreatic Cancer Trial (NorPACT) - 1
This study evaluate the additional effect of adding chemotherapy prior to resection of a pancreatic head malignancy. The patients will be randomized into two groups; surgery first (control group) and neoadjuvant chemotherapy…
- Trial name
- NCT02919787
- Testing
- 5-FU, Oxaliplatine, Irinotecan
- Where
- 13 sites in Denmark, Finland and 2 more
- Volunteers
- 140 people
- Sponsor
- Oslo University Hospital
Ovarian Cancer, Small Cell Lung Cancer
A Study of LG00313112 in Participants With Advanced Solid Malignancies Harboring a TP53 Y220C Mutation
This is a first-in-human, Phase 1/2, open-label study evaluating the safety, tolerability, pharmacokinetics, pharmacodynamics, and efficacy of LG00313112 in participants with advanced solid malignancies harboring a TP53 Y220C…
- Conditions
- Ovarian Cancer, Small Cell Lung Cancer, Non Small Cell Lung Cancer, Colorectal Cancer
- Trial name
- NCT07752875
- Testing
- LG00313112
- Volunteers
- 250 people
- Sponsor
- LG Chem
Pancreas Cancer
Preoperative CA 19.9 Level Predicts Lymph Node Metastasis in Resectable Adenocarcinoma of the Head of the Pancreas.
In our multicenter retrospective study, preoperative CA 19.9 levels predicts the presence of lymph node metastasis at final histology in patients underwent pancreatoduodenectomy for pancreatic ductal adenocarcinoma .
- Trial name
- ICALYRA (NCT05959213)
- Volunteers
- 2,034 people
- Sponsor
- Fondazione Policlinico Universitario Campus Bio-Medico
Pancreatic Ductal Adenocarcinoma, Gastric Cancer
Lead-212 PSV359 Therapy for Patients With Solid Tumors
Phase I/IIa image-guided, alpha-particle therapy study of [203Pb]Pb-PSV359 and [212Pb]Pb-PSV359 in patients with solid tumors that are known to be Fibroblast Activation Protein (FAP)-positive.
- Conditions
- Pancreatic Ductal Adenocarcinoma, Gastric Cancer, Esophageal Cancer, Colorectal Cancer
- Trial name
- NCT06710756
- Testing
- [203Pb]Pb-PSV359, [212Pb]Pb-PSV359
- Where
- 16 sites in United States
- Volunteers
- 112 people
- Sponsor
- Perspective Therapeutics
Local Tumor Spread, Advanced Cancer
Quality of Life After Biliodigestive Anastomosis (BDA) or Stents to Treat Biliary Obstruction in Pancreas Cancer
To compare the quality of life (QoL) in patients receiving a bilioenteric anastomosis vs. endoscopical stenting for palliation of biliary obstruction due to locally unresectable or metastatic pancreatic cancer.
- Conditions
- Local Tumor Spread, Advanced Cancer, Metastasized, Pancreatic Cancer Non-resectable
- Trial name
- BYPAPA (NCT01887041)
- Testing
- Stent, Biliodigestive anastomosis
- Where
- Germany
- Volunteers
- 24 people
- Sponsor
- Universitätsklinikum Hamburg-Eppendorf
Selected Advanced Solid Tumors, Colorectal Cancer (CRC)
SKL35501 With SKL35502 Imaging in Adults With NTSR1 Positive Advanced Solid Tumors
This Phase 1, open-label study will evaluate two investigational radiopharmaceuticals in adults with selected advanced or metastatic solid tumors.
- Conditions
- Selected Advanced Solid Tumors, Colorectal Cancer (CRC), Pancreatic Ductal Adenocarcinoma (PDAC), Biliary Tract Cancer (BTC)
- Trial name
- NCT07812805
- Testing
- SKL35501, SKL35502
- Where
- 5 sites in United States, South Korea
- Volunteers
- 100 people
- Sponsor
- SK Life Science, Inc.
Tumor, Solid, Lung Cancer
Carbon Nanoparticle-Loaded Iron in the Treatment of Advanced Solid Tumor
Independently developed by Sichuan Yingrui Pharmaceutical Technology Co., Ltd., CNSI-Fe is an innovative anti-cancer drug with Fe2+ as the active ingredient, which exerts anti-tumor effects by regulating the ferroptosis pathway.
- Conditions
- Tumor, Solid, Lung Cancer, Pancreas Cancer, Thyroid Cancer
- Trial name
- NCT07433283
- Testing
- Carbon Nanoparticle-Loaded Iron [CNSI-Fe], Carbon Nanoparticle-Loaded Iron
- Where
- 9 sites in China
- Volunteers
- 54 people
- Sponsor
- Sichuan Enray Pharmaceutical Sciences Company
Pancreatic Cancer, BRAF Mutant Colorectal Cancer
A Study of LGK974 in Patients With Malignancies Dependent on Wnt Ligands
The primary purpose of this study was to find the recommended dose of LGK974 as a single agent and in combination with PDR001 that can be safely given to adult patients with selected solid malignancies that had progressed despite…
- Conditions
- Pancreatic Cancer, BRAF Mutant Colorectal Cancer, Melanoma, Triple Negative Breast Cancer
- Trial name
- NCT01351103
- Testing
- LGK974, PDR001
- Where
- 20 sites in United States, Canada and 5 more
- Volunteers
- 185 people
- Sponsor
- Novartis Pharmaceuticals
Gastric Cancer, Colon Cancer
Safety and Efficacy of CEA-targeted CAR-T for CEA-positive Advanced Malignant Solid Tumors
This study is a single-arm, open-label, dose-escalating + dose-expansion clinical study, aiming to evaluate the safety and efficacy of CEA-targeted CAR-T cell preparations, and to preliminarily observe the study drug in…
- Conditions
- Gastric Cancer, Colon Cancer, Rectal Cancer, Esophageal Cancer
- Trial name
- NCT05538195
- Testing
- CEA-targeted CAR-T cells
- Where
- China
- Volunteers
- 17 people
- Sponsor
- Chongqing Precision Biotech Co., Ltd
Head and Neck Cancer, Pancreatic Cancer
Ketamine for Preventing Depression in Patients Undergoing Treatment for Pancreatic or Head and Neck Cancers
The primary purpose of this study is to see if it is safe to give patients with pancreatic or head and neck cancer a low dose of the FDA approved anesthetic drug ketamine at the same time they receive radiation and/or…
- Conditions
- Head and Neck Cancer, Pancreatic Cancer, Depression
- Trial name
- NCT02442739
- Testing
- Ketamine
- Where
- United States
- Sponsor
- Cedars-Sinai Medical Center
Lung, Prostate, Breast, Colon, Pancreatic, Renal, Bladder,Thyroid, Ovarian, Head and Neck,GI (Foregut - Esophagus),GI (Midgut) Cancer, Cancer of the Ovarian, Head and Neck,GI (Foregut - Esophagus),GI (Midgut), Sarcoma Cancer
Optional Sub-study to Intraoperative Imaging With ICG Registry
The primary goal of this optional sub-study is to record what tissues fluoresce in the operating room, and then to identify if these lesions are cancer when the histopathology is performed.
- Conditions
- Lung, Prostate, Breast, Colon, Pancreatic, Renal, Bladder,Thyroid, Ovarian, Head and Neck,GI (Foregut - Esophagus),GI (Midgut) Cancer, Cancer of the Ovarian, Head and Neck,GI (Foregut - Esophagus),GI (Midgut), Sarcoma Cancer, Cancer of Neuro-onc, Parathyroid, Desmoid Tumors, Melanoma Cancer
- Trial name
- NCT02651246
- Testing
- data collection
- Where
- United States
- Volunteers
- 291 people
- Sponsor
- Abramson Cancer Center at Penn Medicine
Metastatic Cancer, Solid Tumor
LYT-200 Alone and in Combination With Chemotherapy or Tislelizumab in Patients With Locally Advanced or Metastatic Solid Tumors
A Phase 1/2 Open-label, Multi-center Study of the Safety, Pharmacokinetics, and Anti-tumor Activity of LYT-200 Alone and in Combination with Chemotherapy or Tislelizumab in Patients with Metastatic Solid Tumors
- Conditions
- Metastatic Cancer, Solid Tumor, Pancreatic Cancer, Urothelial Carcinoma
- Trial name
- NCT04666688
- Testing
- LYT-200, Tislelizumab, Gemcitabine/nab-paclitaxel
- Where
- 12 sites in United States
- Volunteers
- 44 people
- Sponsor
- PureTech
Carcinoma, Non-Small-Cell Lung, Squamous Cell Carcinoma of the Head and Neck
A Study of PF-08046054/SGN-PDL1V in Advanced Solid Tumors
This study will test the safety of a drug called PF-08046054/SGN-PDL1V alone and with pembrolizumab in participants with solid tumors. It will also study the side effects of this drug.
- Conditions
- Carcinoma, Non-Small-Cell Lung, Squamous Cell Carcinoma of the Head and Neck, Esophageal Squamous Cell Carcinoma, Triple Negative Breast Neoplasms
- Trial name
- NCT05208762
- Testing
- PF-08046054, pembrolizumab
- Where
- 62 sites in United States, Belgium and 9 more
- Volunteers
- 714 people
- Sponsor
- Seagen, a wholly owned subsidiary of Pfizer
Pancreatic Ductal Adenocarcinoma, Colorectal Cancer
FAPi Radioligand OpeN-Label, Phase 1 Study to Evaluate Safety, Tolerability and DosImetry of [Lu-177]-PNT6555; A Dose Escalation Study for TReatment of Patients With Select Solid Tumors (FRONTIER)
This Phase 1 study will evaluate the safety and tolerability of [Ga-68]-PNT6555 and [Lu-177]-PNT6555 in subjects with select solid tumors that have FAP over-expression, in order to determine a recommended Phase 2 dose.
- Conditions
- Pancreatic Ductal Adenocarcinoma, Colorectal Cancer, Esophageal Cancer, Melanoma (Skin)
- Trial name
- NCT05432193
- Testing
- [Ga-68]-PNT6555, [Lu-177]-PNT6555
- Where
- 4 sites in United States, Canada
- Volunteers
- 20 people
- Sponsor
- POINT Biopharma, a wholly owned subsidiary of Eli Lilly and Company